Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Safety, Efficacy and Total Cost of Therapy of Decentralized, Point-of-Care Manufactured Anti-CD19 CAR-T Cells for Relapsed or Refractory B Cell Leukemia and Lymphoma: Results from the First Phase 1 Indian Trial (VELCART)

Palani Hamenth Kumar, Arun Kumar Arunachalam, Mohammed Yasar, Phaneendra Venkateswara Rao Datari, Uday Kulkarni, Sushil Selvarajan, Anu Korula, Aby Abraham, Biju George, Vikram Mathews

Blood (2024) 144 (Supplement 1): 2090.

https://doi.org/10.1182/blood-2024-201902

Published: 2024

Journal Articles

Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Changchun Deng, Paolo F. Caimi, Umar Farooq, Nethrie Idippily, Maria Florencia Giraudo, Jane S. Reese, Sarah Kleinsorge-Block, Daniel Caley, Ryan Stadel, Koen van Besien, Marcos de Lima, Arun Kumar Arunachalam, J. Joseph Melenhorst, David Wald

Blood (2024) 144 (Supplement 1): 94.

https://doi.org/10.1182/blood-2024-206596

Published: 2024

Journal Articles

Safety and Efficacy of Low Dose Versus High Dose Corticosteroid for Graft Versus Host Disease (GVHD): A Systematic Review

Ghulam Shah, Ahda Solangi, Amirta Devi, Arun Kumar, Ranjit Sah, Pradeep Khanal, Sangam Shah, Sanjit Sah, Usama Mirza, Zeeshan Solangi

Blood (2024) 144 (Supplement 1): 7695.

https://doi.org/10.1182/blood-2024-206297

Published: 2024

Journal Articles

Evaluating the Effectiveness and Tolerability of Chimeric Antigen Receptor (CAR) T Cells Therapy in Patient with Systemic Lupus Erythematosus: A Systematic Review

Amirta Devi, Arun Kumar, Ranjit Sah, Sangam Shah, Amita Paudel, Sanjit Sah, Ghulam Shah, Ahda Solangi, Usama Mirza, Zeeshan Solangi

Blood (2024) 144 (Supplement 1): 7694.

https://doi.org/10.1182/blood-2024-206122

Published: 2024

Journal Articles

Evaluating Trends in Hospitalization, Associated Costs and Racial/Socioeconomic Disparities Among Patients with Sickle Cell Disease Using the National Inpatient Sample (NIS) Database

Amirta Devi, Arun Kumar, Ghulam Shah, Zeeshan Solangi, Emeka P. Agudile, Ahda Solangi, Ranjit Sah, Garrett Diltz, Hira Latif

Blood (2024) 144 (Supplement 1): 5341.

https://doi.org/10.1182/blood-2024-199713

Published: 2024

Journal Articles

Primary Analysis of Varnimcabtagene Autoleucel (IMN-003A) in Phase 2 Study (IMAGINE), a First-in-India Industry CD19-Directed CAR-T Cell Therapy for Patients with Relapsed Refractory B Cell Malignancies

Blood (2023) 142 (Supplement 1): 2104.

https://doi.org/10.1182/blood-2023-179424

Published: 2023

Journal Articles

Self-Sustainability with Therapeutic Phlebotomy, a Solution to the National Blood Crisis?

Madhan Srinivasan Kumar, Sumukh Arun Kumar, Rahul Mishra, Manoj Rai, Susan George, George M. Abraham, Kala Seetharaman

Blood (2023) 142 (Supplement 1): 5051.

https://doi.org/10.1182/blood-2023-187612

Published: 2023

Journal Articles

Varnimcabtagene Autoleucel (IMN-003A): Pharmacokinetic Profile with Predominant Naïve and Central Memory Phenotype Demonstrates Sustained In Vivo Persistence and Durable Responses in a First-in-India Industry Phase-2 Study (IMAGINE)

Blood (2023) 142 (Supplement 1): 6876.

https://doi.org/10.1182/blood-2023-179709

Published: 2023

Journal Articles

Trends in Hemophagocytic Lymphohistiocytosis Incidence and Outcomes: A Nationwide Hospital-Based Analysis of 939 Hospitalizations

Manoj Rai, Prabhjot S Bedi, Arun Kuruvila, Sumukh Arun Kumar, Joseph J. Shatzel

Blood (2023) 142 (Supplement 1): 3748.

https://doi.org/10.1182/blood-2023-189424

Published: 2023

Journal Articles

Varnimcabtagene Autoleucel (IMN-003A): Differences in T Cell Subset Phenotype in B-ALL and B-NHL Cohorts Did Not Influence Efficacy Outcomes in the Phase-2 Study (IMAGINE)

Blood (2023) 142 (Supplement 1): 6881.

https://doi.org/10.1182/blood-2023-184521

Published: 2023

Journal Articles

Did Physicians Have a Role to Play in National Blood Crisis?

Sumukh Arun Kumar, Ankushi Sanghvi, Maya Gogtay, Harshit Khosla, Susan V George, Ahmad Daniyal Siddiqui

Blood (2022) 140 (Supplement 1): 7883–7884.

https://doi.org/10.1182/blood-2022-160184

Published: 2022

Journal Articles

Early Results from a Phase-2 Study of Varnimcabtagene Autoleucel (IMN-003A), a First-in-India Industry CD19-Directed CAR-T Cell Therapy with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies (IMAGINE Study)

Sharat Damodar, Sunil Bhat, Akshatha Nayak, Pooja Mallya, Bharath Ram S, Ravi Joshi, Deepak MB, Sudarshan Chougule, Anne Roshan Joseph, Gopinadh Jakka, Sudeshna Dhar, Arun Kumar MG, Murugan Palanisamy, Sri Ramulu Elluru, Mohammed Manzoor Akheel, Arun Anand, Anil Kamat

Blood (2022) 140 (Supplement 1): 10343–10344.

https://doi.org/10.1182/blood-2022-166297

Published: 2022

Journal Articles

Response, Peak and Persistence of Varnimcabtagene Autoleucel (IMN-003A), First-in-India Industry CD19-Directed CAR-T Cell Therapy, with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies: Early Results (IMAGINE Study)

Sunil Bhat, Sharat Damodar, Pooja Mallya, Akshatha Nayak, Ravi Joshi, Bharath Ram S, Sudarshan Chougule, Deepak MB, Gopinadh Jakka, Sudeshna Dhar, Anne Roshan Joseph, Arun Kumar MG, Murugan Palanisamy, Jeetendra Kumar, Melina Soares, Pallavi Arasu, Sri Ramulu Elluru, Mohammed Manzoor Akheel, Anil Kamat

Blood (2022) 140 (Supplement 1): 7478–7479.

https://doi.org/10.1182/blood-2022-166650

Published: 2022

Journal Articles

Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial

Vaishali Sanchorawala, Ashutosh D. Wechalekar, Kihyun Kim, Stefan Schönland, Heather J Landau, Kwok Fiona, Kenshi Suzuki, Angela Dispenzieri, Giampaolo Merlini, Raymond Comenzo, Dasha Cherepanov, Vanessa C Hayden, Arun Kumar, Richard Labotka, Douglas V. Faller, Efstathios Kastritis

Blood (2021) 138 (Supplement 1): 4771.

https://doi.org/10.1182/blood-2021-148689

Published: 2021

Journal Articles

Real World Data of Concurrent Arsenic Trioxide and All-Trans Retinoic Acid with Minimal Use of Anthracycline in the Treatment of Acute Promyelocytic Leukemia

Uday Prakash Kulkarni, Sushil Selvarajan, Sharon Lionel, Mithun Abraham Prakash, Hamenth Kumar Palani, Nithya Balasundaram, Arvind Venkatraman, Anu Korula, Anup J Devasia, Fouzia NA, Nancy Beryl Janet, Sukesh Chandran Nair, Aby Abraham, Thenmozhi Mani, Jeyaseelan Lakshmanan, Arun Kumar Arunachalam, Poonkuzhali Balasubramanian, Biju George, Vikram Mathews

Blood (2021) 138 (Supplement 1): 2338.

https://doi.org/10.1182/blood-2021-146362

Published: 2021

Journal Articles

Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial

Blood (2021) 138 (Supplement 1): 2733.

https://doi.org/10.1182/blood-2021-148481

Published: 2021

Journal Articles

Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM)

Meletios A. Dimopoulos, S. Vincent Rajkumar, Sagar Lonial, Wee-Joo Chng, Shinsuke Iida, Maria-Victoria Mateos, Gareth J. Morgan, Arun Kumar, Kaveri Suryanarayan, Alexander Vorog, Andrew Fergus, Richard Labotka

Blood (2021) 138 (Supplement 1): 1656.

https://doi.org/10.1182/blood-2021-150476

Published: 2021

Journal Articles

Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies

Wee-Joo Chng, Sagar Lonial, Gareth J. Morgan, Shinsuke Iida, Philippe Moreau, Shaji Kumar, Philip Twumasi-Ankrah, Arun Kumar, Ajeeta B. Dash, Alexander Vorog, Xiaoquan Zhang, Kaveri Suryanarayan, Richard Labotka, Meletios A. Dimopoulos, S. Vincent Rajkumar

Blood (2021) 138 (Supplement 1): 1678.

https://doi.org/10.1182/blood-2021-147838

Published: 2021

Journal Articles

Germline Variants Contribute Significantly to the Pathogenesis of Aplastic Anemia in India

Aruna Barade, Arun Kumar Arunachalam, Deborah Arul, Anu Korula, Anup J Devasia, Fouzia NA, Kavitha M Lakshmi, Aby Abraham, Vikram Mathews, Biju George, Eunice Sindhuvi Edison

Blood (2021) 138 (Supplement 1): 1105.

https://doi.org/10.1182/blood-2021-148348

Published: 2021

Journal Articles

Haploidentical Natural Killer Cell Therapy As an Adjunct to Stem Cell Transplantation for Refractory Acute Myeloid Leukemia

Uday Prakash Kulkarni, Arun Kumar Arunachalam, Hamenth Kumar Palani, Nithya Balasundaram, Arvind Venkatraman, Anu Korula, Anup J Devasia, Fouzia NA, Sushil Selvarajan, Sharon Lionel, Madhavi Maddali, Aby Abraham, Poonkuzhali Balasubramanian, Biju George, Vikram Mathews

Blood (2021) 138 (Supplement 1): 3827.

https://doi.org/10.1182/blood-2021-149539

Published: 2021

NARROW

Safety, Efficacy and Total Cost of Therapy of Decentralized, Point-of-Care Manufactured Anti-CD19 CAR-T Cells for Relapsed or Refractory B Cell Leukemia and Lymphoma: Results from the First Phase 1 Indian Trial (VELCART)

Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Safety and Efficacy of Low Dose Versus High Dose Corticosteroid for Graft Versus Host Disease (GVHD): A Systematic Review

Evaluating the Effectiveness and Tolerability of Chimeric Antigen Receptor (CAR) T Cells Therapy in Patient with Systemic Lupus Erythematosus: A Systematic Review

Evaluating Trends in Hospitalization, Associated Costs and Racial/Socioeconomic Disparities Among Patients with Sickle Cell Disease Using the National Inpatient Sample (NIS) Database

Primary Analysis of Varnimcabtagene Autoleucel (IMN-003A) in Phase 2 Study (IMAGINE), a First-in-India Industry CD19-Directed CAR-T Cell Therapy for Patients with Relapsed Refractory B Cell Malignancies

Self-Sustainability with Therapeutic Phlebotomy, a Solution to the National Blood Crisis?

Varnimcabtagene Autoleucel (IMN-003A): Pharmacokinetic Profile with Predominant Naïve and Central Memory Phenotype Demonstrates Sustained In Vivo Persistence and Durable Responses in a First-in-India Industry Phase-2 Study (IMAGINE)

Trends in Hemophagocytic Lymphohistiocytosis Incidence and Outcomes: A Nationwide Hospital-Based Analysis of 939 Hospitalizations

Varnimcabtagene Autoleucel (IMN-003A): Differences in T Cell Subset Phenotype in B-ALL and B-NHL Cohorts Did Not Influence Efficacy Outcomes in the Phase-2 Study (IMAGINE)

Did Physicians Have a Role to Play in National Blood Crisis?

Early Results from a Phase-2 Study of Varnimcabtagene Autoleucel (IMN-003A), a First-in-India Industry CD19-Directed CAR-T Cell Therapy with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies (IMAGINE Study)

Response, Peak and Persistence of Varnimcabtagene Autoleucel (IMN-003A), First-in-India Industry CD19-Directed CAR-T Cell Therapy, with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies: Early Results (IMAGINE Study)

Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial

Real World Data of Concurrent Arsenic Trioxide and All-Trans Retinoic Acid with Minimal Use of Anthracycline in the Treatment of Acute Promyelocytic Leukemia

Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial

Interim Analyses of Overall Survival (OS) from the TOURMALINE MM3 & MM4 Studies of Ixazomib Maintenance Following Primary Therapy in Multiple Myeloma (MM)

Progression-Free Survival (PFS) According to the Presence of Adverse Cytogenetic Abnormalities in Patients (pts) with Multiple Myeloma (MM) Receiving Ixazomib (ixa)-Based vs Placebo (pbo)-Based Therapy: A Pooled Analysis of the TOURMALINE-MM1, MM2, MM3, and MM4 Phase 3 Studies

Germline Variants Contribute Significantly to the Pathogenesis of Aplastic Anemia in India

Haploidentical Natural Killer Cell Therapy As an Adjunct to Stem Cell Transplantation for Refractory Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only